The Crystal Structure of Human α2-Macroglobulin Reveals a Unique Molecular Cage

Proteolysis Lab, Molecular Biology Institute of Barcelona, CSIC, Barcelona Science Park c/Baldiri Reixac, 15-21, 08028 Barcelona (Spain)
Angewandte Chemie International Edition (Impact Factor: 11.34). 04/2012; 51(14):3340-4. DOI: 10.1002/anie.201108015
Source: PubMed

ABSTRACT I'm your Venus: The crystal structure of the human methylamine-induced form of α(2) -macroglobulin (α(2) M) shows its large central cavity can accommodate two medium-sized proteinases (see structure, front part clipped off to better show central cavity). Twelve major entrances provide access for small substrates to the cavity and the still-active trapped "prey". The structure unveils the molecular basis of the unique "venus flytrap" mechanism of α(2) M.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cysteine peptidases are key proteolytic virulence factors of the periodontopathogen Porphyromonas gingivalis, which causes chronic periodontitis, the most prevalent dysbiosis-driven disease in humans. Two peptidases, gingipain K (Kgp) and R (RgpA and RgpB), which differ in their selectivity after lysines and arginines, respectively, collectively account for 85% of the extracellular proteolytic activity of P. gingivalis at the site of infection. Therefore, they are promising targets for the design of specific inhibitors. While the structure of mature RgpB is known, little is known about Kgp, which shares only 27% sequence identity. We report the high-resolution crystal structure of a competent fragment of Kgp encompassing the catalytic cysteine peptidase domain and a downstream immunoglobulin superfamily-like domain, which is required for folding and secretion of Kgp in vivo. The structure, which strikingly resembles a tooth, was serendipitously trapped with a fragment of a covalent inhibitor targeting the catalytic cysteine. This provided accurate insight into the active site and suggested that catalysis may require a catalytic triad, C477-H444-D388, rather than the cysteine-histidine dyad normally found in cysteine peptidases. In addition, a 20Å-long solvent-filled interior channel traverses the molecule and links the bottom of the specificity pocket with the molecular surface opposite the active-site cleft. This channel, absent in RgpB, may enhance the plasticity of the enzyme, which would explain the much lower activity in vitro towards comparable specific synthetic substrates. Overall, the present results report the architecture and molecular determinants of the working mechanism of Kgp, including interaction with its substrates.
    Journal of Biological Chemistry 09/2014; DOI:10.1074/jbc.M114.602052 · 4.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Noonan syndrome (NS) is a developmental disorder characterized by short stature, facial dysmorphisms and congenital heart defects. To date, all mutations known to cause NS are dominant, activating mutations in signal transducers of the RAS/mitogen-activated protein kinase (MAPK) pathway. In 25% of cases, however, the genetic cause of NS remains elusive, suggesting that factors other than those involved in the canonical RAS/MAPK pathway may also have a role. Here, we used family-based whole exome sequencing of a case-parent trio and identified a de novo mutation, p.(Arg802His), in A2ML1, which encodes the secreted protease inhibitor α-2-macroglobulin (A2M)-like-1. Subsequent resequencing of A2ML1 in 155 cases with a clinical diagnosis of NS led to the identification of additional mutations in two families, p.(Arg802Leu) and p.(Arg592Leu). Functional characterization of these human A2ML1 mutations in zebrafish showed NS-like developmental defects, including a broad head, blunted face and cardiac malformations. Using the crystal structure of A2M, which is highly homologous to A2ML1, we identified the intramolecular interaction partner of p.Arg802. Mutation of this residue, p.Glu906, induced similar developmental defects in zebrafish, strengthening our conclusion that mutations in A2ML1 cause a disorder clinically related to NS. This is the first report of the involvement of an extracellular factor in a disorder clinically related to RASopathies, providing potential new leads for better understanding of the molecular basis of this family of developmental diseases.European Journal of Human Genetics advance online publication, 18 June 2014; doi:10.1038/ejhg.2014.115.
    European journal of human genetics: EJHG 06/2014; 23(3). DOI:10.1038/ejhg.2014.115 · 4.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The solution structure of complement C3b is crucial for the understanding of complement activation and regulation. C3b is generated by the removal of C3a from C3. Hydrolysis of the C3 thioester produces C3u, an analogue of C3b. C3b cleavage results in C3c and C3d (TED). To resolve functional questions in relation to C3b and C3u, analytical ultracentrifugation and X-ray and neutron scattering studies were used with C3, C3b, C3u, C3c and C3d, using the wild-type allotype with R102. In 50 mM NaCl buffer, atomistic scattering modelling showed that both C3b and C3u adopted a compact structure, similar to the C3b crystal structure in which its TED and MG1 domains (MG: macroglobulin) were connected through the R102-E1032 salt-bridge. In physiological 137 mM NaCl, scattering modelling showed that C3b and C3u were both extended in structure with the TED and MG1 domains now separated by up to 6 nm. The importance of the R102-E1032 salt-bridge was determined using surface plasmon resonance to monitor the binding of wild-type C3d(E1032) and mutant C3d(A1032) to immobilised C3c. The mutant did not bind while the wild-type form did. The high conformational variability of TED in C3b in physiological buffer showed that C3b is more reactive than previously thought. Because the R102-E1032 salt-bridge is essential for the C3b-Factor H complex during the regulatory control of C3b, the known clinical associations of the major C3S (R102) and disease-linked C3F (G102) allotypes of C3b were experimentally explained for the first time. Copyright © 2014, The American Society for Biochemistry and Molecular Biology.
    Journal of Biological Chemistry 12/2014; DOI:10.1074/jbc.M114.605691 · 4.60 Impact Factor